Esperion Therapeutics has agreed to buy fellow biopharmaceutical company Corstasis Therapeutics and its Enbumyst nasal-spray product, for an initial $75 million in cash. Esperion on Tuesday said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results